ÐÏࡱá>þÿ 79þÿÿÿ6ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿì¥Á{À ð¿õbjbjzäzä 4ŽŽõ ÿÿÿÿÿÿ·((‚‚‚‚‚ÿÿÿÿ––––ª–§$<ÆÆÆÆÆµµµ&$($($($($($($$ã&²•)RL$‚µµµµµL$‚‚ÆÆïa$WWWµ.‚Æ‚Æ&$Wµ&$WWŽ’!ø^#ÆÿÿÿÿPÜ—¢ß§ÎÿÿÿÿãŠ"$w$0§$š"Äç)ù^ç) ^#^#ç)‚r# µµWµµµµµL$L$Wµµµ§$µµµµÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿç)µµµµµµµµµ( H: DRUG DISCOVERY AND DEVELOPMENT (MSc/PgDip/PgCert) 57B220B1/61B220VX/62B220VZ Qualifications for entry: A degree or equivalent qualification, at the prescribed standard in Pharmacology, Pharmacy or a relevant Science subject (e.g. Biochemistry, Biomedical Sciences, Biology). Duration: 12 months full-time or 24 months part-time (MSc); 9 months full-time or 18 months part-time (PgDip). Aim: To equip students for careers developing and expanding current knowledge of drug discovery and development. To achieve this the programme will provide a multi-disciplinary approach to the study of drug discovery and development; mechanisms of drug action; preclinical and clinical trials; and regulatory affairs. Content: The programme of taught courses will comprise lectures, tutorials, practical classes and demonstrations. The curriculum includes biochemical and molecular aspects of drug action; drug transport, metabolism and excretion; toxicology; pharmacokinetics; statistics; computing studies; industrial aspects of drug development; therapeutic drug monitoring; the influence of disease on drug handling; drug-drug interactions; the design and conduct of volunteer and clinical trials; monitoring drug safety. Candidates shall be required to attend the following designated programme of courses: Stage 1 MT5003 Drug Metabolism and toxicology (15 credits) BT5010 Small Molecule drug discovery (25 credits) BT5011 Introduction to Bio-Business and the commercialisation of bioscience Research (10 credits) GS50M1 Generic Skills (0 credits) And one of the following electives MB5022 Introduction to Molecular Biology (15 credits) or MT5008 Molecular pharmacology (15 credits) PU5017 Applied Statistics (15 credits) Stage 2 BT5508 Advanced Bio-Business and the commercialisation of bioscience research (15 credits) BT5502 Biologic therapies (25 credits) MT5503 Pharmacokinetics (10 credits) MT5515 Basic Research methods (15 credits) Above courses contribute to degree award. The following courses are available as additional credits MT5501 Pharmacovigilance (5 credits) BT5901 Laboratory techniques core skills (10 credits) Recommended for those conducting a lab based project Stage 3 MT5903 Research Project (60 credits) Diploma candidates may be allowed to transfer to the MSc if they complete the above programme at an appropriate standard. No candidate will be allowed to progress to Stage 3 as an MSc candidate if they fail to achieve an appropriate standard in the taught part of the programme. MSc candidates with a registered medical qualification may be able to carry out a clinical research project in the final stage under supervision of one of the medical staff. Assessment: By practical work, by written essays, written examinations and by oral presentations, or by a combination of these, as prescribed for each course. The dissertation will be assessed and there may be an oral examination on completion of the programme. Candidates must pass all courses at an appropriate standard for the award of the MSc degree. 2LMNg  ‡ ‹ Þ ì È Ð   ' . Z a Œ “ î õ íÞÌÞíº¦•¦•¦•„•¦•saSBSBSBS h½s¾h½s¾CJOJQJ^JaJh½s¾CJOJQJ^JaJ#h½s¾h½s¾>*CJOJQJ^JaJ h:;¨h9’CJOJQJ^JaJ h:;¨hÝd4CJOJQJ^JaJ h:;¨hxìCJOJQJ^JaJ&h:;¨hxì6�CJOJQJ]�^JaJ#h:;¨h9’5�CJOJQJ^JaJ#h:;¨hxì5�CJOJQJ^JaJh:;¨5�CJOJQJ^JaJ#h:;¨h:;¨5�CJOJQJ^JaJ2MN  † ‡ Ç È Æ Ç   & ' Z Œ î òåòòòòòòòòÓÓòÉÉ»»»» ÆSdð¤gdoA dð¤gd½s¾$ Æ0dð¤a$gd:;¨ $dð¤a$gd:;¨ $dð¤a$gd:;¨56p›ÂÃËÌ'NsžŸ*a–—Ÿíßßßßßßßßßßßßͼßßßßßß Æ S„dð¤gdoA ÆS„ dð¤^„ gdoA ÆSdð¤gdoA ÆS„Ðdð¤^„ÐgdoAõ <=ÃÌÓ'.NUyzŸ *1a–— ÄÅÆÀÓŽ™¿ÕôõïáïÏáïáïáïáï¿ïáïáï­ïÏï­›ŠyŠeŠyŠ›&h:;¨hxì6�CJOJQJ]�^JaJ h:;¨hÝd4CJOJQJ^JaJ h:;¨hxìCJOJQJ^JaJ#h:;¨hxì5�CJOJQJ^JaJ#h½s¾h½s¾5�CJOJQJ^JaJh½s¾h½s¾6�CJOJQJaJ#h½s¾h½s¾>*CJOJQJ^JaJh½s¾CJOJQJ^JaJ h½s¾h½s¾CJOJQJ^JaJ Ÿ ÅÆ�ŽôõññäÓÓÓÆ $d¤a$gd:;¨$ Æ„d¤a$gd:;¨ $dð¤a$gd:;¨ ÆSdð¤gdoA21�h:p·5°‚. °ÆA!° "° #� $� %°°Ä°Ä �Äj ˜žžžžžžž666666666vvvvvvvvv666666>666666666666666666666666666¨6666666666¸666666666666hH66666666666666666666666666666666666666666666666666666666666666666°62ÀÐàð 0@P`p€�ÀÐàð2(Øè 0@P`p€�ÀÐàð 0@P`p€�ÀÐàð 0@P`p€�ÀÐàð 0@P`p€�ÀÐàð 0@P`p€�ÀÐàð 0@P`p€�8XøV~ OJPJQJ_HmH nH sH tH J`ñÿJ 9’Normal d¤ÈCJ_HaJmH sH tH ^@^ xì Heading 2$dð¤@&a$>*CJOJPJQJ^JaJDA òÿ¡D Default Paragraph FontRióÿ³R 0 Table Normalö4Ö l4Öaö (k ôÿÁ( 0No List @³ò@ 9’ List Paragraph ^„Ðm$R™@R \0 Balloon Text dð¤CJOJQJ^JaJNþoòÿN \0Balloon Text CharCJOJQJ^JaJPþoòÿ!P xìHeading 2 Char>*CJOJPJQJ^JaJPK!éÞ¿ÿ[Content_Types].xml¬‘ËNÃ0E÷Hüƒå-Jœ²@%é‚ÇŽÇ¢|ÀÈ™$ÉØ²§Uû÷LÒTB¨ l,Ù3÷ž;ãr½µÃ˜œ§J¯òB+$ëG]¥ß7OÙ­V‰�$ùãûÿ©«×îÇ !)OÚ^ýrÍC$ñy@“°íÝö/­yH*œ˜ñ„´½)‘Þµ�÷ß»Š×UDb‚`}"×qÛ‹”J×—–¤ÃX^æ)I`nÌEŒ¼Šp)øèÆli¹V[]Š1M<”àÈÞ�©OÐP“ô6râ=¯‰’zÀgb Ig…Áu��SÙebÖö€OÀ�†ä¾òÃRÁDÛ«™Ÿ·´qu ¯g‹˜Z°¶´®o~ÙºlAp°lxŠpT0­÷­+[}`j×ëõº½zAϰV–2ÍF­ÞÉi–@öqžv·Ö¬5\|‰þʜ̭N§Óle²X¢dsøµÚjcsÙÁ�Å7çð�Îf·»êà ÈâWçðý+­Õ†‹7 ˆÑä`­ÚïgÔ È˜³íJøÀ×j|†‚h(¢K³óD-еß㢠dXÑ©iJÆØ‡(îâx$(Ö ð:Á¥;ä˹!Í I_ÐTµ½S 1£÷êù÷¯ž?EÇž?øéøáÃã?ZBΪmœ„åU/¿ýìÏÇ£?ž~óòÑÕxYÆÿúÃ'¿üüy5Òg&΋/ŸüöìÉ‹¯>ýý»GðM�Geø�ÆD¢›äíó3Vq%'#q¾ÃÓòŠÍ$”8ÁšKýžŠôÍ)f™w9:ĵàå£ x}rÏx‰‰¢œw¢ØîrÎ:\TZaGó*™y8IÂjæbRÆíc|XÅ»‹Ç¿½I u3KGñnD1÷NIBÒsü€� íîRêØu—ú‚K>Vè.EL+M2¤#'šf‹¶i ~™Vé þvl³{u8«Òz‹ºHÈ Ì*„æ˜ñ:ž(W‘☕ ~«¨JÈÁTøe\O*ðtHG½€HYµæ–}KNßÁP±*ݾ˦±‹ŠTѼ�9/#·øA7ÂqZ…Ð$*c?�¢íqUßån†èwðNºû%Ž»O¯·ièˆ4 =3¾¼N¸¿ƒ)cbJ u§VÇ4ù»ÂÍ(TnËáâ 7”Ê_?®�ûm-Ù›°{UåÌö‰B½w²ÒzÏû¨nœ”ÇÊœ"Z úàxŠÕJÜZšìp;‹“Êì ØåÞ{/å<óP;™Ž,)''KÐQÛk5—›òqÚöÆpN†Ç8¯KÝGbÂe“¯„ ûS“ÙdùÌ›­\17 êpõaí>§°SR!Õ–‘ 3•…K4'+ÿrÌzQ TT£³I±²Áð¯Ivt]KÆc⫲³K#Úvö5+¥|¢ˆDÁ±‰ØÇà~ª O@%\w˜Š _ànN[ÛL¹Å9Kºò�˜ÁÙqÌÒgåV§hžÉn R!ƒy+‰ºUÊn”;¿*&å/H•rÿÏTÑû Ü>¬Ú>\ Œt¦´=.TÄ¡ ¥õûS; Zà~¦!¨à‚ÚüäPÿ·9gi˜´†C¤Ú§!ö# Bö ,™è;…X=Û»,I–2UW¦Vì9$l¨kàªÞÛ=A¨›j’•ƒ;î{–A£P79å|s*Y±÷Úø§;›Ì ”[‡MC“Û¿±hf»ª]o–ç{oY=1k³yV³ÒVÐÊÒþ5E8çVk+ÖœÆËÍ\8ðâ¼Æ0X4D)Ü!!ýö?*|f¿vè uÈ÷¡¶"øx¡‰AØ@T_²�ÒÒŽ q²ƒ6˜4)kÚ¬uÒVË7ë ît ¾'Œ­%;‹¿Ïiì¢9sÙ9¹x‘ÆÎ,ìØÚŽ-45xödŠÂÐ8?ÈǘÏdå/Y|t½ß &LILð�J`è¡& ù-G³tã/ÿÿPK! Ñ�Ÿ¶'theme/theme/_rels/themeManager.xml.rels„�M Â0„÷‚wooÓº‘&݈ЭÔ„ä5 6?$Qìí ®,.‡a¾™i»—�Éc2Þ1hª:é•qšÁm¸ìŽ@RN‰Ù;d°`‚Žo7íg‘K(M&$R(.1˜r'J“œÐŠTù€®8£�Vä"£¦AÈ»ÐH÷u} ñ›|Å$½b{Õ–Pšÿ³ý8‰g/]þQAsÙ…(¢ÆÌà#›ªLÊ[ººÄßÿÿPK-!éÞ¿ÿ[Content_Types].xmlPK-!¥Ö§çÀ6 0_rels/.relsPK-!ky–ƒŠtheme/theme/themeManager.xmlPK-!0ÝC)¨¤Ötheme/theme/theme1.xmlPK-! Ñ�Ÿ¶'² theme/theme/_rels/themeManager.xml.relsPK]­ õ ÿÿÿÿõ õ Ÿõ ðLð# ð †ÁÅÁ@ñÿÿÿ€€€÷ð’ðð0ð( ð ððB ðS ð¿Ëÿ ?ð$)*0 ÷  ÷ 3 !!1LMMÅô ÷ ãL>ºÚä�ÿÿÿÿÿÿÿÿÿIk²;ÆVš)ÿÿÿÿÿÿÿÿÿ5G¤B+ìÿÿÿÿÿÿÿÿÿ0¬j” šÿÿÿÿÿÿÿÿÿõsÃ}À‹ ›ÿÿÿÿÿÿÿÿÿ„Є˜þÆÐ^„Ð`„˜þOJQJ^Jo(" „ „˜þÆ ^„ `„˜þOJQJ^Jo( „p„˜þÆp^„p`„˜þ.„@ „˜þÆ@ ^„@ `„˜þ.„„˜þÆ^„`„˜þ.„à„˜þÆà^„à`„˜þ.„°„˜þư^„°`„˜þ.„€„˜þÆ€^„€`„˜þ.„P„˜þÆP^„P`„˜þ. „ „˜þ^„ `„˜þOJQJo(·ð€„p„˜þ^„p`„˜þOJQJ^Jo(o€ „@ „˜þ^„@ `„˜þOJQJo(§ð€ „„˜þ^„`„˜þOJQJo(·ð€„à„˜þ^„à`„˜þOJQJ^Jo(o€ „°„˜þ^„°`„˜þOJQJo(§ð€ „€„˜þ^„€`„˜þOJQJo(·ð€„P„˜þ^„P`„˜þOJQJ^Jo(o€ „ „˜þ^„ `„˜þOJQJo(§ð„Є˜þÆÐ^„Ð`„˜þOJQJ^Jo(" #„ „˜þÆ ^„ `„˜þOJQJ^Jo( „p„˜þÆp^„p`„˜þ.„@ „˜þÆ@ ^„@ `„˜þ.„„˜þÆ^„`„˜þ.„à„˜þÆà^„à`„˜þ.„°„˜þư^„°`„˜þ.„€„˜þÆ€^„€`„˜þ.„P„˜þÆP^„P`„˜þ.„Є˜þ^„Ð`„˜þCJOJQJaJo(·ð€„ „˜þ^„ `„˜þOJQJ^Jo(o€ „p„˜þ^„p`„˜þOJQJo(§ð€ „@ „˜þ^„@ `„˜þOJQJo(·ð€„„˜þ^„`„˜þOJQJ^Jo(o€ „à„˜þ^„à`„˜þOJQJo(§ð€ „°„˜þ^„°`„˜þOJQJo(·ð€„€„˜þ^„€`„˜þOJQJ^Jo(o€ „P„˜þ^„P`„˜þOJQJo(§ð „Є˜þ^„Ð`„˜þOJQJo(·ð€„ „˜þ^„ `„˜þOJQJ^Jo(o€ „p„˜þ^„p`„˜þOJQJo(§ð€ „@ „˜þ^„@ `„˜þOJQJo(·ð€„„˜þ^„`„˜þOJQJ^Jo(o€ „à„˜þ^„à`„˜þOJQJo(§ð€ „°„˜þ^„°`„˜þOJQJo(·ð€„€„˜þ^„€`„˜þOJQJ^Jo(o€ „P„˜þ^„P`„˜þOJQJo(§ðãL> 5G¤B Ik²;0¬jõsÃ}ÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿbvtÂ܉x:á–,~VP$ÖÛP…$c@%âýZärfM<¹—         (N2Hndµ�J`TôÖÊúÚœ\þ¶à`n,þœ/ò¼.¬Î¤ÔV                 /Y_"å ÈB O`/) v3Ýd4·5<;oAôCJ²(P+X\�MaÓrcCmn³Bwß!‡9’›'¤:;¨u)³å)³°Qµ½s¾lÂÓQÉësÖ!\Ú«Ûópèxì cþõ ÷ ÿ@2:22õ ˜@ÿÿUnknownÿÿÿÿÿÿÿÿÿÿÿÿ G�ÿ*àAxÀ ÿTimes New Roman5�€Symbol3.� ÿ*àCxÀ ÿArial7.�ÿáÿ¬@ ŸCalibriY� CG TimesTimes New Roman5.� ÿ.á[`À)ÿTahoma?=� ÿ*àCxÀ ÿCourier New;�€WingdingsA�ÿàÿ$BŸCambria Math"qˆðÐh…ó'—'�ó'È- �È- !ð  ´´��20ï ï 3ƒðüýHX ðÿ $Päÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿ9’2!xx  ÜÿÿMelanie McCannadr152      þÿà…ŸòùOh«‘+'³Ù0t�˜¤°ÈÔè ø $ 0 < HT\dläMelanie McCann Normal.dotmadr1526Microsoft Office Word@¤“Ö@Ná]SnÍ@fîìSnÍ@’{‹ß§ÎÈ- þÿÕÍÕœ.“—+,ù®DÕÍÕœ.“—+,ù®@ü hp�˜ ¨ °¸ÀÈ Ð ÝäºÚÁÏÍøï   TitlexHìô0Pl_NewReviewCycle_AdHocReviewCycleID_EmailSubject _AuthorEmail_AuthorEmailDisplayName_ReviewingToolsShownOnceäÕ"ª SENAS: New programme proposalr.j.findlay@abdn.ac.ukFindlay, Robert J þÿÿÿ !"#$%þÿÿÿ'()*+,-þÿÿÿ/012345þÿÿÿýÿÿÿ8þÿÿÿþÿÿÿþÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿRoot Entryÿÿÿÿÿÿÿÿ ÀF04¦¢ß§Î:€1Tableÿÿÿÿÿÿÿÿ*WordDocumentÿÿÿÿÿÿÿÿ4SummaryInformation(ÿÿÿÿ&DocumentSummaryInformation8ÿÿÿÿÿÿÿÿÿÿÿÿ.CompObjÿÿÿÿÿÿÿÿÿÿÿÿrÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿþÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿÿþÿ ÿÿÿÿ ÀF Microsoft Word 97-2003 Document MSWordDocWord.Document.8ô9²q